Atamparib (RBN-2397)

Atamparib (RBN-2397) is a potent, orally active NAD+ competitive PARP7 inhibitor with an IC50 value of less than 3 nM. Atamparib (RBN-2397) can directly inhibit cell proliferation and restore type I interferon signaling by inhibiting PARP7 in tumor cells to stimulate innate or adaptive antitumor immune responses.